Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study

BACKGROUND: Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas...

Descripción completa

Detalles Bibliográficos
Autores principales: Diessner, Joachim, Wischnewsky, Manfred, Blettner, Maria, Häusler, Sebastian, Janni, Wolfgang, Kreienberg, Rolf, Stein, Roland, Stüber, Tanja, Schwentner, Lukas, Bartmann, Catharina, Wöckel, Achim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167411/
https://www.ncbi.nlm.nih.gov/pubmed/27992550
http://dx.doi.org/10.1371/journal.pone.0168730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167411/
https://www.ncbi.nlm.nih.gov/pubmed/27992550
http://dx.doi.org/10.1371/journal.pone.0168730

Ejemplares similares